The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective DOI Creative Commons
Suvro Biswas, Shafi Mahmud, Mohasana Akter Mita

et al.

Frontiers in Medicine, Journal Year: 2022, Volume and Issue: 9

Published: May 6, 2022

The emergence of several novel SARS-CoV-2 variants regarded as concern (VOCs) has exacerbated pathogenic and immunologic prominences, well reduced diagnostic sensitivity due to phenotype modification-capable mutations. Furthermore, latent more virulent strains that have arisen a result unique mutations with increased evolutionary potential represent threat vaccine effectiveness in terms incoming existing variants. As result, resisting natural immunity, which leads higher reinfection rates, avoiding vaccination-induced immunization, lack effectiveness, become crucial problem for public health around the world. This study attempts review genomic variation pandemic impact emerging variations based on clinical characteristics management immunization effectiveness. goal this is gain better understanding link between genome level polymorphism, symptom manifestation, current vaccination instance VOCs.

Language: Английский

Potential Antiviral Activity of Lactiplantibacillus plantarum KAU007 against Influenza Virus H1N1 DOI Creative Commons
Irfan A. Rather, Majid Rasool Kamli, Jamal S. M. Sabir

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(3), P. 456 - 456

Published: March 16, 2022

The development of antiviral resistance has exacerbated a growing threat to public health. As result, there is increasing demand for unconventional antivirals that can effectively replace the presently in-use drugs. Lactic acid-producing bacteria (LAB) are among most common used in food industry. These play an essential role fermentation many foods and feed. Additionally, these considered more economical, efficient, safe “nutraceuticals” health care arsenal. Therefore, we carried out screening molecular characterization raw camel milk LAB isolates tested their inhibitory activity against influenza virus H1N1. strain exhibited highest H1N1 virus, confirmed by hemagglutination assay, was identified as Lactiplantibacillus plantarum KAU007. study also non-cytotoxic behavior CFCS isolated from KAU007 MDCK cells, approving its safety concern mammalian cells. Besides, at 5 10 mg/mL significantly decreased level IFN-γ (p < 0.001 p 0.001) IL-6 0.005) dose-dependent manner, respectively. This preliminary report about anti-influenza milk. reinforces contains beneficial with antagonistic properties virus.

Language: Английский

Citations

8
Safety of an inactivated COVID-19 vaccine (CoronaVac) in children aged 7-14 years in Taizhou, China DOI Creative Commons
Dongsheng Zhang, Xue-ping Bao, Jingjing Zhu

et al.

Diagnostic Microbiology and Infectious Disease, Journal Year: 2024, Volume and Issue: 109(2), P. 116253 - 116253

Published: March 16, 2024

Our study aimed to evaluate the safety of CoronaVac, an inactivated vaccine made by Sinovac, in children aged 7-14. We conducted a parent-administered online survey monitor adverse reactions after vaccinating Taizhou, China, from February 15, 2021, January 19, 2022. 767 parents completed receiving questionnaire via WeChat. Overall, 15.3 % (117/767) experienced effects first dose, and 12.2 (88/724) second. Muscle pain was most common reaction post-first dose (10.0 %), while localized or itching at injection site second (7.6 %). In conclusion, has low incidence side effects. The mild moderate, transient, nature these further boosts parents' confidence their children.

Language: Английский

Citations

1
COVID-19 vaccine booster strategy: striving for best practice DOI Creative Commons
Mine Durusu Tanrıöver, Murat Akova

The Lancet Global Health, Journal Year: 2022, Volume and Issue: 10(6), P. e774 - e775

Published: April 23, 2022

As we enter the third year of COVID-19 pandemic, policy makers need pragmatic data about performance different vaccination regimens for informed decisions and prioritisation, because placebo-controlled studies are no longer feasible ethical reasons. Furthermore, there is a evidence protective effectiveness vaccines against symptomatic or severe in real-world settings, which unselected individuals from every age risk groups vaccinated.In The Lancet Global Health, Alejandro Jara colleagues1Jara A Undurraga EA Zubizarreta JR et al.Effectiveness homologous heterologous booster doses an inactivated SARS-CoV-2 vaccine: large-scale prospective cohort study.Lancet Glob Health. 2022; (published online April 23.)https://doi.org/10.1016/S2214-109X(22)00112-7Summary Full Text PDF PubMed Scopus (25) Google Scholar report CoronaVac (Sinovac Biotech), AZD1222 (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech) boosters after completion primary schedule with two CoronaVac. results based on analyses dataset gathered single centralised immunisation registry nearly 11·2 million aged 16 years older, representing 80% Chilean population. Participants study were followed up until Nov 10, 2021; therefore, follow-up potentially excludes three omicron subvariants (BA.1, BA.1.1, BA.2).Compared vaccination, adjusted vaccine was calculated as 78·8% (95% CI 76·8–80·6) CoronaVac, 96·5% (96·2–96·7) booster, 93·2% (92·9–93·6) booster. rates 86·3% hospitalisation 86·7% COVID-19-associated deaths following three-dose schedule. Corresponding higher schedules, at 96·1% 97·7% 96·8% 98·1% deaths. Additional indicated that provided improved high level protection outcomes death than two-dose Although strategy showed effectiveness, it note median women men who received 69·1 years, compared 43·5 45·2 67·0 66·3 difference when evaluating relatively lower regimen has been shown both antibody T-cell responses compromised people 55 older.2Medeiros GX Sasahara GL Magawa JY al.Reduced t cell to coronavirus among above old.Front Immunol. 13812126 Crossref (4) ScholarAlthough by supports so-called mix-and-match approach, optimum strategies dosing intervals provide maximum benefit context variants circulation be defined. Zeng colleagues3Zeng G Wu Q Pan H al.Immunogenicity safety dose immune persistence schedule, healthy adults: interim single-centre, double-blind, randomised, phase 2 clinical trials.Lancet Infect Dis. 22: 483-495Summary (78) reported neutralising titres induced declined near below limit seropositivity 6 months; however, given 8 months second led strong boost response. Aikawa colleagues4Aikawa NE Kupa LVK Medeiros-Ribeiro AC al.Increment immunogenicity large population patients autoimmune rheumatic diseases.Ann Rheum March 11.)https://doi.org/10.1136/annrheumdis-2021-222096Crossref (7) initial series resulted robust response even diseases, greater those still seronegative first vaccinations. Khong colleagues5Khong KW Liu D Leung KY al.Antibody combination platforms covid-19 variant.Vaccines. 10: 160Crossref (19) combinations (BNT162b2-CoronaVac-BNT162b2 CoronaVac-CoronaVac-BNT162b2) delta (B.1.617.2) variant, but much titre BA.1 subvariant. Two-dose mRNA rapid pronounced loss infection variant6Andrews N Stowe J Kirsebom F al.Covid-19 (B.1.1.529) Variant.N Engl Med. 2.)https://doi.org/10.1056/NEJMoa2119451Crossref (364) disease before surge variant.7Nordström P Ballin M Nordström Risk infection, hospitalisation, 9 retrospective, total Sweden.Lancet. 399: 814-823Summary (48) Because do not cover surge, cannot estimate schedules settings. McMenamin colleagues8McMenamin ME Nealon Lin Y al.Vaccine 1 Hong Kong.medRxiv. 24.) (preprint).https://doi.org/10.1101/2022.03.22.22272769Google analysed Dec 31, 2021, 8, 2022, covering fifth wave BA.2 lineage Kong. Three highly mortality all groups, yet effects have investigated.The insights how manage vaccination. It now clear that, world where equity utopia, scientists can only strive best use available reach attainable benefit. mix match strategy, including priming thereafter, seems realistic policy. vaccinated. In BA.2). Compared investigated. We declare competing interests. Effectiveness studyOur suggest complete provides COVID-19, death. Heterologous outcomes, providing additional support approach. Full-Text Open Access

Language: Английский

Citations

7
Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial DOI Creative Commons

Samar Samoud,

Jihène Bettaieb, Mariem Gdoura

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(8), P. 1329 - 1329

Published: Aug. 5, 2023

(1) Background: This study aimed to compare the immunogenicity of mix-and-match CoronaVac/BNT162b2 vaccination homologous CoronaVac/CoronaVac regimen. (2) Methods: We conducted a simple-blinded randomized superiority trial measure SARS-CoV-2 neutralization antibodies and anti-spike receptor binding domain (RBD) IgG concentrations in blood samples participants who had received first dose CoronaVac vaccine followed by BNT162b2 or vaccine. The primary endpoint for was serum-neutralizing antibody level with percentage inhibition at 90% 21–35 days after boost. A difference 25% between groups considered clinically relevant. (3) Results: Among 240 eligible participants, data were available 100 randomly allocated group versus 99 group. regimen elicited significantly higher levels neutralizing (median 96%, interquartile range (IQR) (95–97) median 94%, IQR (81–96) 13,460, (2557–29,930) 1190, (347–4964) compared Accordingly, subjects > (90.0%) (60.6%). Interestingly, no severe events reported within 30 second both groups. (4) Conclusions: Our showed terms immunogenicity, thus constituting proof-of-concept supporting use inactivated vaccines strategy while ensuring good safety.

Language: Английский

Citations

3
The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective DOI Creative Commons
Suvro Biswas, Shafi Mahmud, Mohasana Akter Mita

et al.

Frontiers in Medicine, Journal Year: 2022, Volume and Issue: 9

Published: May 6, 2022

The emergence of several novel SARS-CoV-2 variants regarded as concern (VOCs) has exacerbated pathogenic and immunologic prominences, well reduced diagnostic sensitivity due to phenotype modification-capable mutations. Furthermore, latent more virulent strains that have arisen a result unique mutations with increased evolutionary potential represent threat vaccine effectiveness in terms incoming existing variants. As result, resisting natural immunity, which leads higher reinfection rates, avoiding vaccination-induced immunization, lack effectiveness, become crucial problem for public health around the world. This study attempts review genomic variation pandemic impact emerging variations based on clinical characteristics management immunization effectiveness. goal this is gain better understanding link between genome level polymorphism, symptom manifestation, current vaccination instance VOCs.

Language: Английский

Citations

5